Corcept Therapeutics’ (CORT) Overweight Rating Reiterated at Piper Sandler

Piper Sandler reaffirmed their overweight rating on shares of Corcept Therapeutics (NASDAQ:CORT) in a report published on Thursday morning,Benzinga reports. Piper Sandler currently has a $165.00 target price on the biotechnology company’s stock, up from their prior target price of $88.00.

Several other analysts have also weighed in on the stock. UBS Group set a $135.00 price objective on shares of Corcept Therapeutics in a research note on Thursday, May 28th. Wolfe Research cut shares of Corcept Therapeutics from a “peer perform” rating to an “underperform” rating and set a $50.00 price target for the company. in a report on Monday, July 27th. Weiss Ratings reaffirmed a “hold (c-)” rating on shares of Corcept Therapeutics in a research note on Wednesday, June 24th. Zacks Research upgraded shares of Corcept Therapeutics from a “strong sell” rating to a “hold” rating in a report on Monday, May 4th. Finally, HC Wainwright increased their price objective on shares of Corcept Therapeutics from $95.00 to $165.00 and gave the stock a “buy” rating in a research report on Thursday. One analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, Corcept Therapeutics currently has a consensus rating of “Moderate Buy” and a consensus target price of $119.17.

Corcept Therapeutics Price Performance

Shares of Corcept Therapeutics stock opened at $114.49 on Thursday. The stock’s 50-day moving average is $84.77 and its 200 day moving average is $56.78. Corcept Therapeutics has a one year low of $28.66 and a one year high of $122.21. The firm has a market cap of $12.38 billion, a price-to-earnings ratio of 272.60 and a beta of 0.47.

Corcept Therapeutics (NASDAQ:CORT) last issued its earnings results on Wednesday, July 29th. The biotechnology company reported $0.36 earnings per share for the quarter, topping analysts’ consensus estimates of $0.02 by $0.34. The business had revenue of $256.15 million during the quarter, compared to the consensus estimate of $221.15 million. Corcept Therapeutics had a return on equity of 8.26% and a net margin of 6.52%.The firm’s revenue for the quarter was up 31.7% on a year-over-year basis. During the same period in the previous year, the company posted $0.29 earnings per share. On average, sell-side analysts expect that Corcept Therapeutics will post 1.13 EPS for the current fiscal year.

Insider Transactions at Corcept Therapeutics

In other news, insider Sean Maduck sold 75,000 shares of Corcept Therapeutics stock in a transaction dated Wednesday, May 27th. The shares were sold at an average price of $65.59, for a total transaction of $4,919,250.00. Following the completion of the transaction, the insider directly owned 8,977 shares in the company, valued at $588,801.43. This trade represents a 89.31% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director James N. Wilson sold 10,000 shares of the business’s stock in a transaction dated Tuesday, June 16th. The stock was sold at an average price of $83.20, for a total transaction of $832,000.00. Following the sale, the director directly owned 1,094,543 shares of the company’s stock, valued at approximately $91,065,977.60. The trade was a 0.91% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last three months, insiders sold 300,000 shares of company stock valued at $22,088,050. Corporate insiders own 20.70% of the company’s stock.

Institutional Trading of Corcept Therapeutics

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Handelsbanken Fonder AB raised its stake in shares of Corcept Therapeutics by 28.1% in the second quarter. Handelsbanken Fonder AB now owns 36,881 shares of the biotechnology company’s stock worth $3,207,000 after purchasing an additional 8,100 shares during the last quarter. Breakwater Capital Group purchased a new position in shares of Corcept Therapeutics during the second quarter valued at approximately $246,000. Evanson Financial LLC purchased a new position in shares of Corcept Therapeutics during the second quarter valued at approximately $1,085,000. GAMMA Investing LLC grew its holdings in Corcept Therapeutics by 54.0% during the second quarter. GAMMA Investing LLC now owns 4,640 shares of the biotechnology company’s stock worth $403,000 after buying an additional 1,627 shares in the last quarter. Finally, Pacer Advisors Inc. grew its holdings in Corcept Therapeutics by 56.8% during the first quarter. Pacer Advisors Inc. now owns 3,184 shares of the biotechnology company’s stock worth $128,000 after buying an additional 1,154 shares in the last quarter. 93.61% of the stock is owned by institutional investors.

Trending Headlines about Corcept Therapeutics

Here are the key news stories impacting Corcept Therapeutics this week:

• Positive Sentiment: Corcept reported second-quarter earnings of $0.36 per share, well above the $0.02 analyst consensus, while revenue reached $256.15 million versus expectations of $221.15 million. Revenue increased 31.7% year over year, helping drive the stock to a new 12-month high. Corcept Therapeutics Reaches New 12-Month High After Better-Than-Expected Earnings
• Positive Sentiment: Piper Sandler initiated or reiterated an “Overweight” rating, adding to the bullish analyst sentiment surrounding Corcept’s growth outlook. Corcept Therapeutics Earns Overweight Rating from Piper Sandler
• Positive Sentiment: HC Wainwright sharply raised its Q3 2026 EPS estimate to $0.78 from $0.34 and lifted its full-year 2026 forecast to $2.15 from $0.80. The firm maintained a “Buy” rating and a $165 price target, implying continued confidence in near-term earnings momentum.
• Neutral Sentiment: Analyst coverage remains mixed: HC Wainwright’s revised estimates imply strong 2026 earnings growth, but the firm reduced several 2027 quarterly forecasts and lowered FY2027 EPS to $3.95 from $5.38. This suggests expectations for longer-term growth have moderated.
• Negative Sentiment: Some investors may be concerned that the stock’s rapid rise has already priced in much of LIFYORLI’s potential. A recent analysis described the drug as likely to become a blockbuster but warned that Corcept’s valuation leaves limited room for disappointment. Corcept Therapeutics: LIFYORLI Is Likely a Blockbuster, But the Valuation Already Knows It

About Corcept Therapeutics

Corcept Therapeutics is a clinical-stage biopharmaceutical company focused on discovering and developing drugs that modulate the effects of cortisol, a hormone implicated in a range of severe metabolic, oncologic and psychiatric disorders. The company’s scientific platform centers on selectively targeting the glucocorticoid receptor to counteract the harmful consequences of excess cortisol, a strategy designed to address diseases with significant unmet medical needs.

The company’s flagship marketed product, Korlym (mifepristone), is approved in the United States for the treatment of hyperglycemia secondary to Cushing’s syndrome in patients who have type 2 diabetes or glucose intolerance and are not candidates for surgery.